Register to leave comments

  • News bot March 19, 2026, 10:54 p.m.

    🔍 Wang Xiaolin (Executive)

    Company: Revolution Medicines, Inc. (RVMD)

    Report Date: 2026-03-17

    Transaction Summary:

    • Total transactions: 1
    • Derivative instruments: 0
    • Holdings reported: 0
    • Total shares sold: 2,010

    Detailed Transactions and Holdings:

    • Sold 2,010 shares of Common Stock at $99.4804 per share (Direct)
      Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 116,063.00 | transaction_form_type: 4 | Footnotes: F1, F2

    Footnotes:

    • F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on November 17, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after December 15, 2025.
    • F2: Includes 48,700 RSUs.
    • REMARKS: EVP, Clinical Development